Description: Bristol-Myers Squibb Company (NYSE:BMY) is one of the cheap S&P 500 stocks to invest in now. On January 12, Bristol-Myers Squibb announced positive topline results from its Phase 3 SCOUT-HCM clinical trial. This study evaluated Camzyos (mavacamten), which is a cardiac myosin inhibitor/CMI, in adolescent patients aged 12 to under 18 years suffering from symptomatic […]

Description: BMY reports positive late-stage data for Camzyos in adolescents with oHCM, expanding its cardiovascular outlook amid pipeline setbacks and rising competition.

Description: The global Central Nervous System (CNS) therapeutic market is projected to reach US$ 235.87 billion by 2033. This growth is propelled by a combination of unprecedented financial investment, a rich pipeline of novel therapies, and expanding treatment infrastructure across key geographies.Chicago, Jan. 14, 2026 (GLOBE NEWSWIRE) -- The global central nervous system therapeutic market was valued at 129.38 billion in 2024 and is expected to reach US$ 235.87 billion by 2033, growing at a CAGR of 6.90%

Description: Keytruda drives over half of MRK's pharma revenues, but softer Q3 sales put investor focus on whether the blockbuster drug can lift Q4 sales performance.

Description: Leerink analyst David Risinger raised the firm’s price target on Bristol Myers (BMY) to $60 from $54 and keeps an Outperform rating on the shares. The firm sees significant pipeline optionality in 2026 and thus room for additional stock upside potential. Leerink notes the company provided an overview of its pipeline readouts to watch in 2026 and beyond at a conference on January 12, 2026. The company has 12 registrational data readouts from 8 assets anticipated in 2026, most of which represent s

Description: The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Description: NEW HAVEN, Conn., January 14, 2026--BioCT, Connecticut’s life sciences trade organization, is pleased to announce the appointment of four distinguished executives to its Board of Directors. The organization has elected Ranjit Bindra, MD, PhD, Harvey and Kate Cushing Professor of Therapeutic Radiology and Professor of Pathology at Yale School of Medicine and serial bioscience entrepreneur; Angela Cacace, PhD, Chief Scientific Officer, Arvinas; Jennifer Good, Co-Founder, President, and Chief Execu

Description: [220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global T-Cell Engagers Market size & share revenue was valued at approximately USD 2.4 Billion in 2024 and is expected to reach USD 2.5 Billion in 2025 and is expected to reach around USD 18.8 Billion by 2034, at a CAGR of 21.2% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Amgen, Genmab, Roche/Genentech, Ma

Description: AbbVie strikes a Trump drug-pricing pact and a $5.6B cancer licensing deal, cutting U.S. prices while expanding its oncology pipeline.

Description: Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.

Description: Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) ("Oramed") and Lifeward Ltd. (NASDAQ: LFWD) ("Lifeward") today announced the signing of binding agreements for a strategic transaction between Oramed, Lifeward and a certain accredited investor. The transaction includes the transfer to Lifeward of Oramed's proprietary Protein Oral Drug POD™ delivery technology and Oramed obtaining 49.9% beneficial ownership interest in Lifeward upon the satisfaction of certain terms and conditions. In addit

Description: We recently published 10 Stocks With Crazy Gains. Tempus AI Inc. (NASDAQ:TEM) was one of the top performers on Monday. Tempus AI snapped a two-day losing streak on Monday, soaring by as much as 15 percent to $76.33 apiece, as investors took heart from a strong demand for its services, having bagged $1.1 billion in […]

Description: BMS looks forward to pivotal readouts for six assets in 2026, ensuring profits after patent expiries for Opdivo and Eliquis.

Description: Investors Eye 2026 Guidance as Tempus AI Tops $1.1B in Contract Value

Description: Retiring at 67 with $6,500 in monthly income places you solidly in middle-class territory, but the financial reality behind that figure is more nuanced than it appears. With average Social Security benefits at $2,017 per month in 2026, a retiree targeting $6,500 needs to generate roughly $4,483 monthly—or $53,796 annually—from personal savings and investments. The ... What $6,500 a Month Really Looks Like in Retirement at 67

Description: Monday is the first day of J.P. Morgan’s annual healthcare investor conference, which draws thousands of investors, analysts, and executives to San Francisco each year. There is ample precedent: Last year, Johnson & Johnson announced a $14.6 billion deal to acquire Intra-Cellular Therapeutics on the first day of the gathering. The Wall Street Journal reported last week that Merck was in talks to buy the biotech Revolution Medicines for roughly $30 billion, but as of late morning, no such agreement had been announced.

Description: Bristol-Myers Squibb Company (NYSE:BMY) is one of the cheap stocks to buy for the next 3 years. On January 9, Scotiabank analyst Louise Chen raised the firm’s price target on Bristol-Myers to $60 from $53, while maintaining a Sector Perform rating on the shares. With the stock trading at an inexpensive valuation and several key […]

Description: The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.

Description: PRINCETON, N.J., January 12, 2026--BMS Announces Positive Topline Results from Phase 3 SCOUT-HCM Trial Evaluating Camzyos in Adolescents with Symptomatic oHCM

Description: CHICAGO, January 11, 2026--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a record Total Contract Value (TCV) of >$1.1 billion as of December 31, 2025. During 2025, Tempus signed data agreements with over 70 customers, spanning both large and mid-sized pharma, including AstraZeneca, GlaxoSmithKline, Bristol Myers Squibb, Pfizer, Novartis, Merck, Abbvie, Daiichi Sankyo, Eli Lilly, Boehringer Ingelheim, and biotechs inc

Description: What Is Driving the Updated Fair Value for Bristol Myers Squibb? The recent shift in Bristol Myers Squibb’s fair value estimate from US$53.55 to US$56.26 per share reflects analysts weighing improving sentiment toward large drugmakers against mixed views on the company’s own positioning. On one hand, some research points to a sector coming out of a cyclical trough, with better macro conditions, more FDA approvals, stronger clinical data, and increased M&A activity lifting expectations for...

Description: In early January 2026, UBS upgraded Bristol-Myers Squibb after highlighting its broad drug pipeline, new clinical trial initiations, and progress on products aimed at easing upcoming patent expirations. This combination of analyst confidence and visible pipeline activity underscores how Bristol-Myers Squibb is working to balance patent risks with future drug launches across oncology, cardiovascular, and neuroscience. We’ll now examine how UBS’s upgrade, anchored in confidence around...

Description: NEW YORK, Jan 9 (Reuters) - Healthcare dealmakers are heading to San Francisco this weekend betting on a new wave of mega-mergers in 2026 that could eclipse the industry’s standout years of 2019 and 2021 when such tie-ups approached half a trillion dollars, according to more than a dozen ​top bankers and lawyers. Ahead of the week-long 43rd annual J.

Description: JNJ cuts U.S. drug prices under a Trump deal, gains a tariff reprieve, and accelerates a $55 billion push to expand domestic manufacturing.

Description: BMY shares have surged in the past six months, driven by Opdivo, Reblozyl and a guidance raise, as growth drugs offset mounting generic pressure

Description: CAMBRIDGE, England, January 09, 2026--Enhanced Genomics (‘Enhanced’ or ‘the Company’), the biotechnology company pioneering 3D multi-omics to rapidly identify high-confidence, genetically validated drug targets for common diseases, today announced Katerina Leftheris, Ph.D. has joined its Board of Directors. Katerina’s appointment as a Director forms part of the Company’s ongoing strategy to expand its internal therapeutics pipeline for drug targets identified using its 3D multi-omics platform.

Description: The New Jersey pharma will now offer some of its branded medicines on the US government-created DTC platform, TrumpRx.gov.

Description: SAN FRANCISCO, January 08, 2026--Biotech Showcase™ Provides Private and Micro- to Mid-Cap Public Company Executives One-Stop Access to Investors, Pharma Partners and Media

Description: Bristol-Myers Squibb (BMY) has been drawing attention after its shares closed at $56.72, leaving investors weighing how recent price moves and mixed growth metrics might fit into a broader long term thesis. See our latest analysis for Bristol-Myers Squibb. The recent 1 day share price return of 4.23% builds on short term momentum, with a 30 day share price return of 9.77% and a 90 day gain of 26.95%, while the 3 year total shareholder return of 9.60% decline shows that longer term holders...

Description: If you are wondering whether Bristol-Myers Squibb is priced attractively right now, you are not alone. This article walks through the key numbers that matter for value focused investors. The share price recently closed at US$54.42, with returns of 0.4% over 7 days, 4.4% over 30 days, 1.8% year to date, 0.1% over 1 year, negative 12.9% over 3 years and 1.4% over 5 years. Taken together, these figures present a mixed picture for anyone thinking about long term value. Recent headlines around...

Description: The big news in the drug sector is the emergence of GLP-1 weight loss drugs, but dig deeper, and you'll find relatively cheap industry giants to consider.

Description: Alumis shares soar as the biotech firm’s envudeucitinib meets all primary and secondary endpoints in a Phase 3 trial. Here’s how you should play ALMS shares in 2026.

Description: The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Description: Amsterdam, the Netherlands, January 7, 2026 – Scenic Biotech, a pioneer in the field of modifier therapies for severe diseases, today announced a license and research agreement with Ono Pharmaceutical Co., Ltd. to utilize Scenic’s Cell-Seq platform for the discovery of novel therapeutic targets. “This collaboration with Ono Pharmaceutical represents another strong validation of our platform’s ability to uncover new disease biology and identify novel targets for rare and common indications,” said

Description: Bristol Myers (BMY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Description: Incyte's phase III study of Monjuvi combo for first-line DLBCL treatment met primary and key secondary goals, paving the way for a 2026 FDA filing.

Description: Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Description: While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...

Description: Pharmaceutical companies are getting a fresh look for a range of drugs in development, plus a regulatory reprieve.

Description: Cash has flowed into oil stocks following the U.S.’s seizing of Venezuelan President Nicolás Maduro.

Description: PRINCETON, N.J., January 02, 2026--Bristol Myers Squibb to Present at J.P. Morgan's 44th Annual Healthcare Conference

Description: REPL shares soar 131.1% over the past three months after the FDA accepts its resubmitted BLA for the RP1/Opdivo combo in advanced melanoma.

Description: <body><p>STORY: :: Bristol Myers Squibb </p><p>:: File</p><p>Drugmakers plan to raise U.S. prices on at least 350 branded medications in 2026, including vaccines and blockbuster cancer treatment Ibrance.</p><p>:: CVS</p><p>That's according to data provided exclusively to Reuters by healthcare research firm 3 Axis Advisors.</p><p>The hikes come even as the Trump administration is pressuring drugmakers for cuts.</p><p>:: CVS</p><p>The number of price increases is up from the same point last year while the median price hike of four percent is in line with 2025.</p><p>The increases do not reflect any rebates to pharmacy benefit managers and other discounts.</p><p>:: Boehringer Ingelheim</p><p>Drugmakers also plan to cut the list prices on around nine drugs including diabetes treatment Jardiance, which is dropping 40%.</p><p>It is among the 10 drugs for which the U.S. government negotiated a lower price for the Medicare program for people aged 65 and older in 2026.</p><p>:: Pfizer</p><p>A health policy researcher tells Reuters these deals are being announced as transformative when, in fact, they really just nibble around the margins in terms of what is really driving high prices for prescription drugs in the U.S.</p><p>:: CVS</p><p>U.S. patients currently pay by far the most for prescription medicines, often nearly three times more than in other developed nations.</p><p>Pfizer announced the most list price hikes, on around 80 different drugs including cancer drug Ibrance, and its COVID vaccine, which is going up 15%.</p><p>:: Pfizer</p><p>:: File</p><p>Pfizer said in a statement it had adjusted the average list price of its innovative medicines and vaccines for 2026 below the overall rate of inflation.</p><p>:: CVS</p><p>More price hikes and cuts can be expected in early January, which is historically the biggest month for drugmakers to raise prices.</p></body>

Description: These stocks can be great sources of portfolio growth in the years ahead.

Description: List prices to rise an average of 4% despite federal pressure to curb costs.

Description: Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Description: Bristol Myers Squibb's growth drugs rose 17% in the first nine months of 2025, helping offset a 16% legacy drug sales decline.

Description: Bristol-Myers Squibb Company (NYSE:BMY) is included among the 14 Best Pharma Dividend Stocks to Buy in 2026. On December 15, Goldman Sachs raised the firm’s price target on Bristol-Myers Squibb Company (NYSE:BMY) to $57 from $51 and kept a Neutral rating on the shares. Bristol-Myers Squibb Company (NYSE:BMY) presents a measured balance between risk and […]

Description: AMGN edges out its rival with stronger growth estimates, a broad portfolio boost from Horizon, and momentum from key drugs like Repatha and Tezspire.

Description: The stock has been on the rebound for several months, but can it keep the momentum going?

Description: The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.

Description: Investors seeking reliable dividends will find that this trio of healthcare stocks offers an exciting combination of safety, growth, and income.

Description: The GLP-1 fight just entered a new round, and it highlights why these three out-of-favor drug makers are worth a deep dive.

Description: Bristol Myers Squibb could become the pharmaceutical industry’s turnaround story for 2026. Shares are off 9% in 2025 after a series of drug pipeline disappointments, while major patent expirations, like one for cancer drug Revlimid, could cause earnings to fall 5% in 2026 and another 5% in 2027. At the current price, investors are paying little for Bristol Myers’ pipeline, led by Cobenfy, a schizophrenia drug being tested as a treatment for psychosis among Alzheimer’s patients, and Milvexian, a treatment of atrial fibrillation and strokes.

Description: If you are looking for high yields, this drug maker and this device maker are both worth a deep dive today.

Description: AMGN signs a pricing deal with the Trump administration, cutting U.S. drug costs, expanding DTC access and securing tariff relief tied to domestic investment.

Description: The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.

Description: Bristol-Myers Squibb (BMY) has quietly staged a comeback, with the stock up about 17% over the past month and roughly 23% in the past 3 months, catching the attention of value focused investors. See our latest analysis for Bristol-Myers Squibb. That rebound sits against a more muted backdrop, with the share price still showing a slightly negative year to date return and a modest 1 year total shareholder return. This suggests sentiment has only recently started to improve as investors reassess...

Description: Bristol-Myers Squibb Company (NYSE:BMY) is included among the Best Stocks for a Dividend Achievers List. Several of the largest US and European drugmakers struck agreements with President Donald Trump on December 19 to voluntarily lower the prices of certain medicines. The move comes as the administration pushes to tie US drug prices more closely to […]

Description: BMY has agreed to supply Eliquis free of charge to Medicaid starting in 2026 and will also donate seven tons of the active pharmaceutical ingredient used in Eliquis.

Description: Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Description: XLV and similar healthcare ETFs are gaining momentum as strength in biotech, increased AI adoption, and rising defensive demand position the sector for year-end leadership.

Description: CYTK enters a new era as FDA approval of Myqorzo transforms it into a commercial biotech, opening a long-term growth runway in cardiology.

Description: Amgen and eight other pharma giants struck deals with the Trump administration to cut U.S. drug prices while gaining tariff relief and manufacturing incentives.

Description: The startup’s filing comes during a broader biotech recovery that’s made some industry watchers optimistic IPOs could rebound next year.

Description: Bristol-Myers Squibb Company (NYSE:BMY) is one of the best stocks to buy for the next 5 years. On December 15, Goldman Sachs raised the firm’s price target on Bristol-Myers Squibb to $57 from $51, while maintaining a Neutral rating on the shares. Earlier on December 4, Bristol-Myers Squibb announced that the US FDA approved Breyanzi (lisocabtagene […]

Description: The clearance is the first in Cytokinetics’ lengthy history and pits its drug Myqorzo against Bristol Myers’ Camzyos, which is on its way to topping $1 billion in sales this year.

Description: Bristol-Myers Squibb Company (NYSE:BMY) is one of the Best Stocks to Invest in for the Next 3 Years. On December 15, BofA upgraded the company’s stock to “Buy” from “Neutral” with a price objective of $61, an increase from $52, given the company’s R&D pipeline, as reported by The Fly. As per the firm, 4-6 programs are expected […]

Description: Key Insights Institutions' substantial holdings in Bristol-Myers Squibb implies that they have significant influence...

Description: Bristol Myers Squibb (BMY) closed at $54.19 in the latest trading session, marking a +1.61% move from the prior day.

Description: Dow Jones stock Merck and eight other bellwether pharma companies struck drug-pricing agreements with the Trump administration on Friday.

Description: President Trump announced deals with nine major drug makers in a move to reduce pharmaceutical prices, granting a three-year break on trade tariffs if they invest more into US manufacturing. Market Domination Overtime host Jared Blikre breaks down the news. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime.

Description: The most recent pledges mean 14 of the 17 drugmakers targeted by Trump this summer have agreed to lower prices for the Medicaid program for low-income and disabled people, sell discounted drugs directly to consumers and launch new medicines for the same prices in the US as they do abroad. “American drug prices will come down fast and furious, and will soon be among the lowest in the developed world,” Trump said during an event in the Oval Office.

Description: Cytokinetics won its first Food and Drug Administration approval late Friday, leading shares to jump in after-hours action.

Description: The companies, including Bristol-Myers Squibb, GSK and Merck, would avoid potential U.S. tariffs in return.

Description: Health care stocks rose late Friday afternoon, with the NYSE Health Care Index increasing 0.8% and t

Description: The Trump administration has talked tough on drug prices, but the impact of its deals with drugmakers so far has been limited.

Description: PRINCETON, N.J., December 19, 2025--Bristol Myers Squibb Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans

Description: Nine pharmaceutical companies including Merck and GSK agreed to lower certain U.S. prices for their medicines in a new round of industry pacts with the Trump administration. The companies agreed to reduce U.S. prices on drugs to levels comparable with prices charged in other wealthy countries, which are generally much lower. Merck, for example, said it would make diabetes drugs Januvia and Janumet available to eligible American patients at a cash price that is 70% off the current list price through a direct-to-patient program.

Description: All three major US stock indexes were up in late-morning trading Friday, as the artificial-intellige

Description: The estate of late beauty mogul Sydell Miller’s is now listing the roughly 20,000-square-foot unit for $78.9 million, ending rumors the tech billionaire bought it late last year.

Description: MRK faces looming Keytruda LOE, falling Gardasil sales and pricing pressure, but new products, pipeline and planned cost savings aim to offset the headwinds.

Description: We recently published 12 Stocks on Jim Cramer’s Radar. Bristol-Myers Squibb Company (NYSE:BMY) is one of the stocks aon Jim Cramer’s radar. Bristol-Myers Squibb Company (NYSE:BMY) is one of the largest pharmaceutical companies in the world. The firm has seen some attention from analysts in December. For instance, Jefferies reiterated a Buy rating and a $68 […]

Description: Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Description: The global pulmonary embolism market is poised for growth from 2025 to 2035, fueled by rising cases of deep vein thrombosis (DVT) and pulmonary embolism (PE) due to escalating obesity rates and sedentary lifestyles. Key drivers include improved diagnostics, Direct Oral Anticoagulants (DOACs), and heightened awareness. Despite the growth, high treatment costs and complications, such as bleeding risks, pose significant challenges, especially in lower-income regions. Top market players include Sano

Description: The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?

Description: PRINCETON, N.J., December 18, 2025--Bristol Myers Squibb to Report Results for Fourth Quarter 2025 on February 5, 2026

Description: We recently compiled a list of 9 Most Undervalued Pharma Stocks to Buy Right Now. Bristol-Myers Squibb Company is one of the most undervalued stocks on our list. On Friday, December 12, 2025, TheFly reported that Guggenheim upgraded BMY’s stock rating from Neutral to Buy and set a new price target of $62, reflecting growing […]

Description: The healthcare industry has never been a great source of dividends -- that alone makes these companies exceptional.

Description: Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.

Description: Harbour is eligible for payments of $90m, with potential development and commercial milestones of up to $1.035bn.

Description: Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced a multi-year, global strategic collaboration and license agreement with Bristol Myers Squibb to discover and develop next-generation multi-specific antibodies.

Description: Market Domination host Josh Lipton outlines the stories driving interest in some of Monday's trending tickers, including Mars Snacking's acquisition of Kellanova (K); Bank of America's upgrade of Bristol Myers (BMY); and Goldman Sachs's bullish calls on Marriott (MAR), Hilton (HLT), and Las Vegas Sands (LVS). To watch more expert insights and analysis on the latest market action, check out more Market Domination.

Description: US equity indexes closed lower Monday as technology stocks continued to face pressure following last

Description: Health care stocks rose late Monday afternoon with the NYSE Health Care Index gaining 1.2% and the S

Description: Shares of biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) jumped 3.7% in the afternoon session after BofA Securities upgraded the company's stock from "Neutral" to "Buy" and increased its price target.

Description: Bristol-Myers Squibb (BMY) offers a favorable risk/reward heading into 2026, supported by four to si

Description: BMY shares are rebounding after a strong Q3, lifted by rising demand for Opdivo, Reblozyl and Camzyos, even as legacy drugs face generic pressure.

Description: Pre-Market Stock Futures: Futures are trading higher on Monday as we head into the final trading weeks of 2025. All of the major indices were hit hard on Friday as investors began a big rotation last week out of the AI stocks that have led the market higher since ChatGPT was introduced over three years ... Here Are Monday’s Top Wall Street Analyst Research Calls: Bristol-Myers Squibb, GE Vernova, KLA Corp., Klaviyo, Las Vegas Sands, ServiceNow, and More

Description: In recent days, Bristol Myers Squibb’s board approved a 1.6% increase in its quarterly common dividend to US$0.63 per share for February 2026 and reaffirmed its preferred dividend, while the company also secured FDA Priority Review for an Opdivo label expansion in advanced classical Hodgkin lymphoma and new approval for Breyanzi in relapsed or refractory marginal zone lymphoma. Together with extensive hematology data at the ASH meeting and progress in AI-enabled drug discovery...

Description: These dividend growth machines could have considerable upside for long-term investors.

Description: Here are three stocks offering attractive yields of up to 4.9%, each backed by strong businesses.

Description: Bristol Myers Squibb (BMY) closed the most recent trading day at $52.41, moving +2.36% from the previous trading session.

Description: Arcus Biosciences stock plunged Friday, reversing a nearly 300% gain, after its Gilead Sciences-partnered cancer regimen failed.

Description: If you are wondering whether Bristol-Myers Squibb is quietly becoming a value opportunity or just a classic value trap, you are in the right place to unpack what the current share price is really telling us. The stock has edged up about 5.1% over the last month after a softer year to date, with the price still down 9.8% since January and around 4.5% lower over the past year. This suggests sentiment is shifting but not yet fully recovered. Recently, investors have been focused on...

Description: Shares of biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) jumped 2.6% in the afternoon session after an analyst at Guggenheim upgraded the company's stock from "Neutral" to "Buy" and set a new price target of $62.

Description: Pfizer and Bristol Myers Squibb are deeply out-of-favor drugmakers, but one could be the better turnaround candidate if you think long term.

Description: BMY gets a priority FDA review for Opdivo's use in previously untreated advanced Hodgkin lymphoma, reinforcing its oncology momentum.

Description: Merck leans on a fast-growing pipeline and new product launches to aid long-term growth as Keytruda's 2028 LOE nears.

Description: Roblox downgraded, Lululemon upgraded: Wall Street's top analyst calls

Description: Pre-Market Stock Futures: The futures are trading mixed as we get set to close out a wild and woolly week that saw a touch of just about everything. The Federal Reserve, as expected, cut rates again and indicated that another cut could come in 2026. Oracle Corp. (NASDAQ: ORCL), which has been on fire this ... Here Are Friday’s Top Wall Street Analyst Research Calls: Bristol-Myers Squibb, Citigroup, Lululemon Athletica, PayPal, Roblox, Soundhound AI, and More

Description: The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?

Description: Bristol-Myers Squibb has seen its fair value estimate nudged slightly higher to about $53.55 per share, even as analysts bake in a marginally higher discount rate of roughly 6.96% and a deeper projected revenue decline of around -5.34%. This combination reflects cautious recognition that sector wide underperformance and a potentially less punitive policy backdrop could support a gradual rerating, even while expectations for top line growth remain subdued. Stay tuned to see how investors can...

Description: The 67th American Society of Hematology (ASH) Annual Meeting, held December 6-9, 2025, in Orlando, Florida, showcased groundbreaking clinical advances in multiple myeloma treatment from leading biopharmaceutical companies. The conference featured unprecedented efficacy data demonstrating potential functional cures and innovative approaches across novel immunotherapies, bispecific antibodies, and next-generation targeted agents, signaling a major shift in how the disease is managed.

Description: The global acute lymphocytic leukemia (ALL) market is set for substantial growth from 2025 to 2035, fueled by advances in chemotherapy, targeted therapies, and immunotherapy. Particularly affecting children and aggressive in adults, ALL is increasingly treated with personalized medications like Tyrosine Kinase Inhibitors and CAR-T cell therapy, transforming patient outcomes. Despite challenges like high treatment costs and drug resistance, the demand for innovative combination therapies is risin

Description: PRINCETON, N.J., December 11, 2025--US FDA Grants Priority Review to Bristol Myers Squibb's Application for Opdivo (nivolumab) Plus Chemotherapy Combination for Classic Hodgkin Lymphoma

Description: PRINCETON, N.J., December 10, 2025--Bristol Myers Squibb Announces Dividend Increase

Description: Bristol-Myers Squibb Company (NYSE:BMY) is one of the best pharma stocks to invest in. On December 4, Jefferies reiterated a Buy rating on Bristol-Myers Squibb Company (NYSE:BMY) with a price target of $68. The same day, Scotiabank lifted the price target on Bristol-Myers Squibb Company (NYSE:BMY) to $53 from $45 while maintaining a Sector Perform rating […]

Description: Investors are currently so focused on one type of drug that even good companies are being left on the sidelines.

Description: Bristol-Myers Squibb (BMY) has been quietly rebuilding momentum, with the stock up around 8% over the past month even as its one year return remains slightly negative. That disconnect is drawing fresh investor attention. See our latest analysis for Bristol-Myers Squibb. That recent 30 day share price return of about 8% contrasts with a negative year to date move and an 8.5% decline in one year total shareholder return, suggesting early but improving momentum as investors reassess risk and...

Description: Pharma ETFs like IHE are poised to surge as the UK-US zero-tariff deal raises UK drug prices and strengthens major U.S. players' outlook.

Description: Teva holds bullish momentum, trading above key SMAs, as branded drugs and biosimilars drive growth despite generics softness.

Description: The global Merkel Cell Carcinoma (MCC) market is rapidly evolving, driven by advancements in immunotherapy and a surge in early diagnoses. Merkel cell carcinoma, a rare, aggressive skin cancer mainly affecting older adults, is increasingly being treated with immune checkpoint inhibitors like Keytruda and Opdivo, which have revolutionized patient survival rates. The market faces challenges with the high cost of treatments impacting accessibility. Key players such as Merck, Bristol Myers Squibb, a

Description: BioNTech (BNTX) said Tuesday it and Bristol Myers Squibb (BMY) reported interim phase 2 data showing

Description: MONTREAL, December 09, 2025--Ability Biotherapeutics, a biotechnology company advancing logic-gated antibody therapies for cancer and autoimmune diseases, today announced the appointment of Angèle Maki, PhD, as Chief Business Officer (CBO).

Description: Global interim Phase 2 data in locally advanced/metastatic triple-negative breast cancer (”TNBC”) show encouraging antitumor activity for investigational therapy pumitamig (BNT327/BMS986545) plus chemotherapy in first- and second-line patientsPumitamig plus chemotherapy achieved confirmed objective response rate (cORR) of 61.5%, unconfirmed ORR (uORR) of 71.8% and disease control rate (DCR) of 92.3% irrespective of PD-L1 expression levelsData highlight the potential of pumitamig for patients wit

Description: PRINCETON, N.J., December 08, 2025--Bristol Myers Squibb Advances Lymphoma Research with New Targeted Protein Degradation and Cell Therapy Data at ASH 2025

Description: Bristol Myers Squibb moves forward with its ADEPT-2 study on Cobenfy, delaying data to next year but boosting investor sentiment.

Description: Bristol-Myers Squibb Company (NYSE:BMY) is included among the 14 Best US Stocks to Buy for Long Term. On December 4, Leerink analyst David Risinger maintained an Outperform rating on Bristol-Myers Squibb Company (NYSE:BMY). The analyst highlighted that the company plans to enroll more patients in the ADEPT-2 study and sees this as a positive development. […]

Description: Bristol-Myers Squibb Company (NYSE:BMY) is one of the stocks Jim Cramer commented on along with the recent macro rally. Cramer mentioned the stock during the episode, as he commented: “Then it might be a comeback to the drug stocks. Why? Well, remember, lots of people think the economy is stalled or in a tailspin. They’re […]

Description: These three drugmakers are all well off their recent highs. Is this a sign of opportunity or risk?

Description: Bristol Myers gains FDA approval to expand Breyanzi's label to R/R marginal zone lymphoma, strengthening its CAR T portfolio amid rising sales.

Description: Praxis shares climbed another 40% on a pair of positive updates on two different drugs. Elsewhere, Bristol Myers’ Breyanzi was cleared for its fifth cancer indication and AstraZeneca expanded a rare disease deal.

Description: PRINCETON, N.J., December 05, 2025--BMS's Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL)

Description: The Tigerlily Foundation (Tigerlily) proudly announces the launch of the Bliss Collective: Brunch & Sip, a new national event series designed to empower women, build community, and amplify awareness of health equity and clinical trial participation through culturally relevant lifestyle experiences. This powerful initiative is being launched in partnership with Bristol Myers Squibb.

Description: Bristol Myers jumps after choosing to continue its phase III ADEPT-2 study on Cobenfy for Alzheimer-related psychosis, delaying data to next year.

Description: Bristol Myers Squibb stock popped Wednesday after the firm delayed a study testing Cobenfy in Alzheimer's disease psychosis.

Description: REDWOOD CITY, Calif., December 03, 2025--C3.ai, Inc. ("C3 AI," "C3," or the "Company") (NYSE: AI), the Enterprise AI application software company, today announced financial results for its fiscal second quarter ended October 31, 2025.

Description: Health care stocks rose late Wednesday afternoon, with the NYSE Health Care Index up 0.5% and the He

Description: Health care stocks rose Wednesday afternoon, with the NYSE Health Care Index and the Health Care Sel

Description: Bristol-Myers Squibb shares rallied 5.6% Wednesday after the drugmaker delayed the release of eagerly awaited clinical-trial results for a potential Alzheimer’s disease treatment. Analysts said investors were relieved that the news wasn’t worse, as there had been some fear that Bristol-Myers would disclose by the end of this month that the study failed outright. The study is testing Bristol-Myers’ Cobenfy schizophrenia drug as a treatment for psychosis in Alzheimer’s disease patients.

Description: Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Description: LOS ANGELES, December 03, 2025--Terray Reaches Milestone in Collaboration with Bristol Myers Squibb

Description: The drugmaker is testing its antipsychotic drug Cobenfy for the treatment of psychosis associated with Alzheimer’s disease.

Description: Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.

Description: Data from the "ADEPT-2" study, which analysts had hoped would arrive before year's end, are now expected sometime in 2026.

Description: PRINCETON, N.J., December 03, 2025--Bristol Myers Squibb Announces Continuation of ADEPT-2 Phase 3 Study in Psychosis Associated with Alzheimer's Disease

Description: Bristol-Myers Squibb Company (NYSE:BMY) ranks among the Best Low Volatility Investments in December 2025. Cantor Fitzgerald reaffirmed its Neutral rating and $45 price target on Bristol-Myers Squibb Company (NYSE:BMY) on November 24. Recent data, according to the firm, offers “tangible evidence that FXIa inhibition can blunt thrombosis while sparing hemostasis,” which bolsters trust in BMY’S […]

Description: Health care stocks declined late Tuesday afternoon, with the NYSE Health Care Index and the Health C

Description: Health care stocks declined Tuesday afternoon, with the NYSE Health Care Index down 0.5% and the Hea

Description: Pfizer's expanding oncology portfolio, rising sales of key therapies, and steady pipeline progress reinforce its long-term cancer strategy momentum.

Description: Veteran gastroenterologist and clinical development leader with deep expertise driving global Phase 2/3 programs across immunology, neurology, and gastrointestinal disease Carlsbad, CA, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company advancing next-generation, once daily, oral PDE4 inhibitor prodrugs for patients with inflammatory and fibrotic diseases, today announced the appointment of James Izanec, M

Description: The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Description: SOUTH SAN FRANCISCO, Calif., December 01, 2025--Cellares, the first Integrated Development and Manufacturing Organization (IDMO), today announced the appointment of Ali Soleymannezhad as Chief Commercial Officer. Soleymannezhad, formerly Chief Commercial Officer at MaxCyte (NASDAQ: MXCT) and Executive Vice President at Tosoh Bioscience, will lead global commercial strategy as the company deploys its network of IDMO Smart Factories across the United States, Europe, and Japan. Soleymannezhad’s app

Description: PRINCETON, N.J., December 01, 2025--Bristol Myers Squibb Data at ASH 2025 Showcases Potential of Hematology Pipeline and Builds Momentum for Next Generation Portfolio

Description: If you are looking to own a stock for the long term, these out-of-favor drugmakers have proven they have what it takes to survive.

Description: In late November, BioNTech raised its full-year 2025 revenue guidance, recognizing US$700 million from its collaboration with Bristol-Myers Squibb, while reporting a net loss for the quarter due to a contractual dispute and continuing investments to transition into a commercial oncology company. An important development from this period is BioNTech’s accelerated clinical advancement, highlighted by ongoing Phase III trials in lung and triple-negative breast cancers and the outlined timeline...

Description: Bristol-Myers Squibb Company (NYSE:BMY) is included among the 15 Best Boring Dividend Stocks to Buy. Bayer repor⁠t​ed positive Phase‌ 3 result⁠s for its FXIa inhi‍bitor as​undexian, h‌itting key efficacy an‍d safety targets and dr‌awing renewed attention to the broader FXIa drug class. Morg​a⁠n Stanley noted this could increase interest i‌n s⁠imilar treatments from Bristol-Myers Squibb […]

Description: Patience will be rewarded for those who stick with these two healthcare stocks.

Description: The pharma stock yields more than 4x the S&P 500 average.

Description: Earlier this week, Bristol Myers Squibb announced that the European Commission approved its CAR-T cell therapy Breyanzi for adults with relapsed or refractory mantle cell lymphoma after at least two prior systemic treatments, including a Bruton’s tyrosine kinase inhibitor. This expanded approval, based on positive trial data, further establishes Breyanzi as a key asset in the company’s oncology portfolio, opening up access for eligible patients across the EU and EEA countries. We’ll now...

Description: Wondering if Bristol-Myers Squibb is a bargain or overpriced? Let’s dig into what’s behind the numbers so you can decide with confidence. After a rocky start to the year, Bristol-Myers Squibb has staged an impressive rebound, gaining 15.6% in the last month and 6.5% in just the past week. However, it is still down 13.3% year-to-date. Investor sentiment has been shaped by headlines ranging from major drug approvals to strategic partnerships, which have fueled recent optimism about...

Description: GILD's HIV strength, new approvals, and rising estimates set it apart as it edges past a challenged rival in growth prospects.

Description: Bristol-Myers has lagged behind the broader S&P 500 Index, and Wall Street remains cautious about this stock.

Description: Bristol Myers strengthens its Opdivo franchise with rising demand and strong uptake of Qvantig, leveraging label expansions to sustain revenue growth.

Description: We came across a bullish thesis on Bristol-Myers Squibb Company on CompoundingLab’s Substack. In this article, we will summarize the bulls’ thesis on BMY. Bristol-Myers Squibb Company’s share was trading at $49 recently. BMY’s trailing and forward P/E were 16.6 and 8 respectively according to Yahoo Finance. Bristol-Myers Squibb Co. (NYSE: BMY) appears modestly undervalued following its recent […]

Description: The global follicular lymphoma market is witnessing growth due to advancements in targeted therapies and immunotherapies. Follicular lymphoma, an indolent form of non-Hodgkin lymphoma, often presents challenges like relapse and treatment resistance, underscoring the need for novel treatment strategies. Innovative therapies such as monoclonal antibodies and CAR T-cell therapies are enhancing patient outcomes by providing more precise and less toxic options compared to traditional chemotherapy. Ke

Description: Bristol Myers wins EC approval to expand Breyanzi's label, adding MCL patients to its growing roster of European CAR-T indications.

Description: PRINCETON, N.J., November 26, 2025--Bristol Myers Squibb to Participate in Citi’s 2025 Global Healthcare Conference

Description: The Centers for Medicare & Medicaid Services said Tuesday it expects to achieve net savings of 44%,

Description: Bristol-Myers Squibb (BMY) shares have seen mixed movement over the past month, with the stock rebounding nearly 9% but still trading below this year’s highs. Investors continue to monitor the company’s performance trends and financials. See our latest analysis for Bristol-Myers Squibb. Even after this month’s strong 8.9% share price return, Bristol-Myers Squibb is still trying to regain its footing following a tough year for total shareholders, who are down nearly 15%. While short-term...

Description: Bristol Myers wins EC approval to expand Breyanzi's label, adding MCL patients to its growing roster of European CAR-T indications.

Description: The trial proved so successful that Bayer plans to reach out to regulators in preparation for submitting the drug candidate for approval.

Description: PRINCETON, N.J., November 24, 2025--BMS Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Mantle Cell Lymphoma

Description: Bayer issued a "surprisingly positive" report for its blood thinner over the weekend, prodding Bristol Myers Squibb stock higher on Monday.

Description: A number of stocks jumped in the afternoon session after a Politico report revealed that the White House plans to pitch a two-year extension of Obamacare subsidies. The proposal would extend subsidies set to expire at the end of the year, with new eligibility limits for individuals with incomes up to 700% of the federal poverty line. These subsidies, a key part of the Affordable Care Act (ACA), help lower the cost of health insurance for consumers, making them crucial for insurers focused on the

Description: The industry is showing enthusiasm for novel technologies that improve safety and carry innovation potential including in vivo CAR-Ts.

Description: PRINCETON, N.J., November 24, 2025--Bristol Myers Squibb to Host Hematology-Focused Investor Event

Description: Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...

Description: Targeted chemotherapy is here. So-called antibody drug conjugates could flip the toxic paradigm on its ear, helping more patients.

Description: The medical technology stock is in a consolidation pattern and testing a key level. The biotech had a beat-and-raise quarter.

Description: Pfizer's new and acquired drugs lift non-COVID revenue, with recent launches and Seagen products driving momentum into 2026 despite looming LOEs.

Description: BMY ends its Librexia ACS study after an interim review shows milvexian is unlikely to meet goals, while other late-stage studies continue.

Description: For Big Pharma, the triumph of developing a new lifesaving blockbuster drug that generates billions in revenue is inevitably followed by the reality that drug patents have an expiration date. It’s a challenge that Bristol Myers Squibb is navigating in real time as it faces a sharp drop in sales of Revlimid, a leading treatment for multiple myeloma that lost patent protection in 2022. Other flagship products approaching their loss of exclusivity in 2028 include Eliquis, a blood thinner, and the intravenous formulation of the cancer immunotherapy Opdivo.

Description: These six top blue-chip dividend stocks remain outstanding ideas for investors seeking to move away from tech stocks.

Description: Cullen Capital Management, LLC, operating under the name Schafer Cullen Capital Management, Inc. (SCCM), has released its “SCCM Value Equity Strategy” third-quarter investor letter. A copy of the letter can be downloaded here. The US equity market continued the rally in the third quarter, with the S&P 500 returning 8.1% and the Russell 1000 Value surging 5.3%. […]

Description: Targeted chemotherapy is here. So-called antibody drug conjugates could flip the toxic paradigm on its ear, helping more patients.

Description: Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Description: MONTREAL, November 19, 2025--Ability Biotherapeutics, a next-generation biotherapeutics company developing logic-gated antibodies for safer and more effective immunotherapies, announces the appointment of Dr. John Burke and Dr. Alan Korman to its Scientific Advisory Board.

Description: PRINCETON, N.J., November 18, 2025--Bristol Myers Squibb Announces Accepted Amounts and Pricing Terms of its Tender Offers

Description: Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease marked by gradual scarring, limiting lung function. The exact cause is unknown, but it combines genetic and environmental factors. With symptoms like shortness of breath and fatigue, IPF lacks a cure, necessitating effective treatments. Increasing cases, driven by aging populations and better diagnosis, spur R&D on new therapies. Companies like Hoffmann-La Roche and Bristol-Myers Squibb innovate with targeted and biologic therapie

Description: [220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global NUT Midline Carcinoma Treatment Market size & share revenue was valued at approximately USD 22.67 Billion in 2024 and is expected to reach USD 26.13 Billion in 2025 and is expected to reach around USD 93.34 Billion by 2034, at a CAGR of 15.26% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Merck & Co.

Description: PRINCETON, N.J., November 18, 2025--Bristol Myers Squibb Announces Early Participation Results, Amendment and Early Settlement of Tender Offers

Description: BMY shares drop after halting the Librexia ACS trial, though other milvexian studies continue with top-line data expected in 2026.

Description: December S&P 500 E-Mini futures (ESZ25) are up +0.02%, and December Nasdaq 100 E-Mini futures (NQZ25) are up +0.09% this morning, pointing to a muted open on Wall Street as cautious sentiment prevailed at the start of a busy week.

Description: Bristol-Myers Squibb Company (NYSE:BMY) is included among the 15 Best Passive Income Stocks to Buy Right Now. On November 13, Scotiabank bega‍n cove‌rage o⁠f Bristol-Myers Squibb Company (NYSE:BMY) with a Sect⁠or Perform rat‍ing and s⁠et a price targ‍et of $4‌5, as reported by The Fly. ‍In the third quart⁠er of 2025, Bristol-Myers Squibb Company (NYSE:BMY) […]

Description: A delivery company got a boost from a new partnership announcement on Friday, Nov. 14, 2025, while the termination of a clinical trial weighed on a pharmaceutical firm.

Description: Shares of Bristol Myers Squibb slumped Friday after the company scrapped a study testing a treatment for acute coronary syndrome.

Description: Health care stocks fell late Friday afternoon, with the NYSE Health Care Index down 0.3% and the Hea

Description: US equity indexes were mixed ahead of Friday's close amid selective dip-buying in technology and inf

Description: US equity indexes were mixed in midday trading on Friday, with technology and energy leading the sec

Description: Bristol said it had decided to stop one of its ongoing Phase 3 trials testing an experimental blood thinner called milvexian.

Description: Major U.S. equities indexes were mixed Friday afternoon, following a sharp decline Thursday fueled by a selloff of tech stocks.

Description: US equity indexes were mixed in midday trading on Friday, with technology and energy leading the sec

Description: Market Catalysts host Julie Hyman tracks several of the day's top trending stock tickers, including Virgin Galactic (SPCE) shares rising while missing third quarter revenue estimates and narrowing its net losses below forecasts, Applied Materials (AMAT) forecasting a drop in chip equipment sales, and Bristol Myers Squibb (BMY) halting its trial for a blood clot drug. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.

Description: Health care stocks were declining premarket Friday, with the Health Care Select Sector SPDR Fund (XL

Description: Pharma ETFs like IHE and PPH are rallying as strong Q3 earnings across major pharmaceutical companies lift sector sentiment.

Description: PRINCETON, N.J., November 14, 2025--Update on Phase 3 Librexia ACS Trial

Description: Bristol Myers Squibb completed a €5 billion senior unsecured note offering and announced an expanded collaboration with Sarah Cannon Research Institute to accelerate development and access to innovative cancer therapies by streamlining clinical trial delivery across more than 200 U.S. locations. This combination of large-scale financing and partnership expansion positions the company to enhance its oncology pipeline while improving financial flexibility for future initiatives. We'll explore...

Description: NVIDIA, Micron Technology and Thermo Fisher lead today's top analyst picks, each showing strong growth trends and strategic advances.

Description: Cytokinetics' shares surge to a 52-week high as investor optimism grows over FDA approval prospects for aficamten.

Description: Bristol Myers' strong Q3 growth portfolio, led by Opdivo and Reblozyl, helped counter declines in legacy drug sales.

Description: Nike upgraded, Dollar Tree downgraded: Wall Street's top analyst calls

Description: The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Description: Kevin Fitzgerald, Alnylam Pharmaceuticals’ chief scientific officer, reveals the hard times that led to RNAi success, and what it takes to pave new roads in biotech.

Description: Turn health into wealth with these three high-yielding dividend stocks.

Description: Health care stocks rose late Wednesday afternoon with the NYSE Health Care Index gaining 1.6% and th

Description: Health care stocks rose Wednesday afternoon, with the NYSE Health Care Index and the Health Care Sel

Description: Precision medicine and next-gen biologics are transforming patient care. Despite cost-related challenges, key players like AbbVie, Johnson & Johnson, and Bristol-Myers Squibb are leading innovations.Dublin, Nov. 12, 2025 (GLOBE NEWSWIRE) -- The "Psoriatic Arthritis Market - A Global and Regional Analysis: Focus on Drug Type and Region - Analysis and Forecast, 2025-2035" has been added to ResearchAndMarkets.com's offering. The growing prevalence of autoimmune diseases, particularly among individu

Description: Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Description: Curious about whether Bristol-Myers Squibb is undervalued or could be a hidden gem? You're not alone, as plenty of investors are asking whether this giant is offering opportunity or risk at today's price. After a long dip early this year, the stock has rebounded, gaining 6.9% in the last week and 10.8% over the past month. However, it remains down 14.2% year to date. Recent headlines have centered on strategic acquisitions in the biotech space and ongoing regulatory developments. Both have...

Description: NASHVILLE, Tenn., November 12, 2025--Sarah Cannon Research Institute (SCRI), one of the world’s leading oncology research organizations conducting community-based clinical trials, and Bristol Myers Squibb (NYSE: BMY), a leading biopharmaceutical company, today announced an expanded strategic collaboration aimed at accelerating the development of innovative cancer therapies and increasing access to clinical trials for patients across the U.S.

Description: The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.4% and the actively trad

Description: The Winn Awards community welcomes 79 new physician-researchers from 23 states NORTHAMPTON, MA / ACCESS Newswire / November 12, 2025 /Originally published by The Robert A. Winn Excellence in Clinical Trials Award Program The Robert A. Winn Excellence ...

Description: Milestone payment reflects continued progress under strategic research collaboration addressing high-need patient populations FDA clearance of IND application triggered a US$ 5 m milestone payment to Evotec HAMBURG, DE / ACCESS Newswire / November ...

Description: Bristol-Myers Squibb Company (NYSE:BMY) is one of the best undervalued stocks to buy under $50. Bristol-Myers Squibb Company (NYSE:BMY) was assigned a Hold rating by Bernstein analyst Courtney Breen on November 3, who maintained the price target at $58. Bristol-Myers Squibb Company (NYSE:BMY) announced strong Q3 results on October 30, with both revenue and EPS […]

Description: Bristol-Myers Squibb Company (NYSE:BMY) is one of the stocks Jim Cramer offered insights on. Answering a caller’s query about the stock, Cramer stated: “I’m backing off on it because I gotta tell you, I’m trying to see some good news in this Cobenfy that I was really all in on and I’m not getting that […]

Description: EDIT reports narrower Q3 loss, boosts revenues on a Bristol Myers milestone, and advances in vivo gene-editing program with EDIT-401.

Description: Bristol-Myers Squibb (BMY) grabbed investor attention after releasing its third-quarter results, which showed a sharp rise in net income and higher revenue guidance for 2025. The company highlighted strength across its growth portfolio. See our latest analysis for Bristol-Myers Squibb. Bristol-Myers Squibb has seen its share price rebound recently, with a 7.5% return over the past month following upbeat quarterly results and an outlook upgrade. However, the 1-year total shareholder return...

Description: With significant upside potential and hedge fund interest, Beam Therapeutics Inc. (NASDAQ:BEAM) secured a spot on our list of the 15 stocks set to explode in 2026. On November 5, 2025, Clear Street increased its price target on Beam Therapeutics Inc. (NASDAQ:BEAM) from $34 to $37, while maintaining a “Buy” rating. The revised target reflected […]

Description: Bristol Myers Squibb's strong Q3 driven by soaring demand for Opdivo, Reblozyl, Breyanzi and Camzyos pushes shares up 7.2% in a month.

Description: Bristol-Myers Squibb Company (NYSE:BMY) is one of the stocks Jim Cramer recently shared thoughts on. Cramer showed his disappointment in the company’s schizophrenia medicine sales, as he commented: “Look, I, my Charitable Trust owns Bristol, looks like a mistake because I, I believed in Cobenfy, which is a, a pretty good product, but it’s not […]

Description: Prothena's Q3 loss widened as revenues fell short of estimates, but its Alzheimer and Parkinson's drug programs gained FDA momentum and key collaborations advanced.

Description: Evotec SE reported its third-quarter 2025 results, showing quarterly sales of €163.89 million and a net loss of €43.09 million, alongside news that it received a US$25 million payment from Bristol Myers Squibb for progress within their neuroscience collaboration. While sales declined year-over-year in the quarter, Evotec’s ongoing partnership achievements underscore the company’s ambitions in innovative drug discovery for neurodegenerative diseases. We'll examine how milestone payments for...

Description: DUBLIN, November 06, 2025--Prothena today reported financial results for the third quarter and first nine months of 2025 and provided business highlights.

Description: Contingent value rights have become common in biotechnology deals. More than half of all transactions this year include them, according to a Jefferies report in October.

Description: The market is expanding due to rising cardiovascular disease prevalence, an aging population, and advancements in treatments like SGLT2 inhibitors. Integration of digital health solutions and personalized medicine are key trends reshaping the landscape, enhancing patient outcomes and quality of life.Dublin, Nov. 06, 2025 (GLOBE NEWSWIRE) -- The "Chronic Heart Failure Market - A Global and Regional Analysis: Analysis and Forecast, 2025-2035" has been added to ResearchAndMarkets.com's offering. Co

Description: With the Federal Reserve likely to continue lowering rates until next summer, now is the time to load the boat on five of our favorite blue-chip dividend giants.

Description: Bristol-Myers Squibb Company's ( NYSE:BMY ) strong earnings report was rewarded with a positive stock price move. Our...

Description: JACKSONVILLE, Fla., November 05, 2025--Redwire Corporation (NYSE:RDW, "Redwire" or the "Company"), a global leader in space and defense technology solutions, today announced results for its third quarter ended September 30, 2025.

Description: PRINCETON, N.J., November 05, 2025--Bristol Myers Squibb Prices €5 Billion of Senior Unsecured Notes

Description: Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.

Description: The startup is advancing a drug licensed from China’s Hengrui Pharma that it claims could be “best-in-class” among a group of similar treatments for hypertrophic cardiomyopathy.

Description: PHILADELPHIA & SAN FRANCISCO, November 04, 2025--Dispatch Bio, a biotech company engineering a universal treatment across solid tumors leveraging its first-in-class Flare platform, today announced a clinical supply and collaboration agreement with Bristol Myers Squibb ("BMS") to support the development of Dispatch’s DISP-10 program. Under the agreement, BMS will provide idecabtagene vicleucel (ide-cel), a BCMA-directed CAR T therapy, for use in Dispatch’s first U.S. Phase 1 trial, expected to in

Description: PRINCETON, N.J., November 03, 2025--Bristol Myers Squibb Showcases New Long-Term and Real-World Data From Cardiovascular Portfolio at the American Heart Association Scientific Sessions

Description: Continued clinical execution of oncology strategy with focus on two pan-tumor programs, including combination approaches to address the full continuum of cancer from early to late disease stagesDemonstrated encouraging anti-tumor activity and manageable safety profile of pumitamig (BNT327/BMS986545), a bispecific antibody candidate targeting PD-L11 and VEGF-A, in first disclosed interim data from global Phase 2 trial in extensive-stage small cell lung cancer Plan to initiate additional pivotal t

Description: Opportunities in the U.S. multiple myeloma market include leveraging cutting-edge therapies like targeted treatments and immunotherapies, capitalizing on aging demographics, increasing disease awareness, and investing in oncology research. Expansion in combination treatments also offers significant potential. U.S. Multiple Myeloma Market U.S. Multiple Myeloma Market Dublin, Nov. 03, 2025 (GLOBE NEWSWIRE) -- The "United States Multiple Myeloma Market Size, Insights, Analysis, Growth Potential and

Description: PRINCETON, N.J., November 03, 2025--Bristol Myers Squibb Announces Cash Tender Offers to Purchase Certain Notes

Description: Bristol-Myers Squibb Company ( NYSE:BMY ) just released its third-quarter report and things are looking bullish...

Description: Bristol-Myers Squibb (BMY) is facing a 6% annual revenue decline projected over the next three years. The company has turned profitable in the past five years, growing earnings by 10.8% per year. Earnings are expected to rise by a moderate 4.6% annually moving forward, although this pace lags the broader US market. Recent results were clouded by a one-off $6.6 billion loss that affected reported earnings quality for the twelve months to September 2025. See our full analysis for Bristol-Myers...

Description: The Craneware Group convened leaders from 25 major U.S. health systems, alongside representatives from Beacon/ESP (Berkeley Research Group) and Apexus, the HRSA 340B Prime Vendor, at its U.S. headquarters this week to align on readiness for the now-approved 340B Rebate Model Pilot Program.

Description: Bristol-Myers Squibb's (BMY) lack of update on its ADEPT-2 phase-3 Alzheimer's psychosis trial or th

Description: Bristol-Myers Squibb Company (NYSE:BMY) is one of the best NYSE stocks to buy and hold for the next decade. On October 27, Bristol Myers Squibb announced new Week 52 data from its pivotal Phase 3 POETYK PsA-1 trial. These results further confirmed the efficacy and safety of Sotyktu (deucravacitinib) for treating adults with active psoriatic […]

Description: The AF market offers opportunities driven by new pipeline drugs such as FXI/FXIa inhibitors addressing bleeding concerns and growing prevalence of treated AF cases. However, growth is challenged by generic erosion of NOACs and competition from cost-effective generics, hindering new entry uptake.Dublin, Oct. 31, 2025 (GLOBE NEWSWIRE) -- The "Atrial Fibrillation: Eight-Market Drug Forecast and Market Analysis - Update" report has been added to ResearchAndMarkets.com's offering.The table below pres

Description: In October 2025, Bristol-Myers Squibb reported positive Phase 3 and Phase 2 trial results for Sotyktu in psoriatic arthritis and systemic lupus erythematosus, and early promising data on its next-generation CD19-targeted CAR T cell therapy across multiple autoimmune diseases at prominent medical conferences. These clinical trial updates highlight Bristol-Myers Squibb's progress in expanding its immunology portfolio, strengthening its pipeline for potential future regulatory approvals and...

Description: Bristol-Myers Squibb Co (BMY) reports robust revenue growth and strategic milestones, raising full-year guidance amid competitive challenges.

Description: Dow Jones stock Merck topped third-quarter forecasts on Thursday, but shares skidded as its challenges with vaccine Gardasil continued.

Description: Shares of biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) jumped 4.3% in the morning session after the company posted third-quarter financial results that beat expectations and raised its full-year sales forecast. Total revenues for the quarter came in at $12.22 billion, an increase of 2.8% from the same period a year ago, surpassing analyst estimates. The company also reported adjusted earnings of $1.63 per share, which was better than anticipated. Following these results, Bristol-Mye

Description: Dublin, Oct. 30, 2025 (GLOBE NEWSWIRE) -- The "Bladder Cancer Market - A Global and Regional Analysis: Analysis and Forecast, 2025-2035" has been added to ResearchAndMarkets.com's offering.The market's growth is primarily driven by the rising incidence of bladder cancer, advancements in diagnostic technologies, and the growing availability of innovative treatments such as immunotherapy and targeted therapies for bladder cancer management.Market Lifecycle StageThe market is currently in the expan

Description: Alnylam and Neurocrine shares tumbled despite upbeat sales reports. Elsewhere, Biogen is dealing with what one analyst called “lackluster” appeal and Bristol Myers’ prized schizophrenia drug again underwhelmed.

Description: Pfizer says ready to ‘pursue all legal avenues to enforce its rights’ against competing bid from Ozempic and Wegovy maker

Description: Market Catalysts host Julie Hyman tracks several of the day's top trending stock tickers, including Estée Lauder (EL) beating profit estimates amid its brand turnaround plan, Mastercard (MA) topping third quarter expectations on its top and bottom lines, and Bristol-Myers Squibb (BMY) raising its revenue outlook. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.

Description: Bristol-Myers' strong Q3 results, powered by Opdivo, Reblozyl and Breyanzi, led to a revenue guidance boost despite legacy drug declines.

Description: The headline numbers for Bristol Myers (BMY) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Description: Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) reported revenue ahead of Wall Streets expectations in Q3 CY2025, with sales up 2.8% year on year to $12.22 billion. The company’s full-year revenue guidance of $47.75 billion at the midpoint came in 0.9% above analysts’ estimates. Its non-GAAP profit of $1.63 per share was 7.6% above analysts’ consensus estimates.

Description: The United States vitiligo market is projected to grow from $202.87 million in 2024 to $320.71 million by 2033, driven by a 5.22% CAGR from 2025. This growth is fueled by increasing awareness, innovative therapies, and improved diagnostic methods. Key treatment advancements include biologics, phototherapy, and topical solutions. Challenges include limited curative options and high treatment costs. States like California, New York, Texas, and Florida lead due to strong healthcare infrastructure.

Description: Bristol-Myers Squibb has significantly underperformed the broader market over the past year, and analysts are cautious about the stock’s prospects.

Description: Bristol Myers (BMY) delivered earnings and revenue surprises of +10.14% and +3.33%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Description: Investing.com -- Bristol-Myers Squibb lifted its full-year outlook slightly after reporting third-quarter earnings and revenue that beat market expectations.

Description: Bristol Myers Squibb hiked its full-year guidance on the back of a strong third quarter underlined by demand for drugs within its growth portfolio. The pharmaceutical giant raised its full-year revenue guidance to a range of $47.5 billion to $48 billion from a previous forecast of $46.5 billion to $47.5 billion. Bristol Myers now sees adjusted earnings between $6.40 and $6.60 a share, versus a previous range of $6.35 to $6.65 a share.

Description: Bristol Myers Squibb added nearly $1 billion to its bottom line in the third quarter as costs came down and revenue climbed on the strength of its newer drugs.

Description: PRINCETON, N.J. (AP) — Bristol Myers Squibb Co. (BMY) on Thursday reported third-quarter earnings of $2.2 billion. On a per-share basis, the Princeton, New Jersey-based company said it had profit of $1.08. Earnings, adjusted for non-recurring costs, came to $1.63 per share.

Description: PRINCETON, N.J., October 30, 2025--Bristol Myers Squibb Reports Third Quarter Financial Results for 2025

Description: NORTHAMPTON, MA / ACCESS Newswire / October 29, 2025 / Bristol-Myers Squibb Company - Recently, the Innovative Cancer Medicines (ICM) initiative announced the enrollment of the first Nigerian patient in a pioneering demonstration project to provide ...

Description: Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) will be reporting results this Thursday morning. Here’s what you need to know.

Description: There’s no better way to generate passive income than dividend stocks. If a stock has a dividend yield higher than the common benchmark, such as the S&P 500, it could be a worthwhile investment. The dividend yield of the S&P 500 averages 1.2%, nearing its record low. Fortunately, there are several dividend stocks with a ... 5 High-Yield Stocks to Anchor Your Portfolio for Half a Decade

Description: Following in the footsteps of David Solomon at Goldman Sachs and Jamie Dimon at JPMorgan, Ark Investments guru Cathie Wood recently warned of the potential for a reality check for the stock market after the massive Artificial Intelligence rally that has driven the major indices to all-time highs over the last three years. Of course, ... Uh Oh !! Cathie Wood Predicts “Reality Check” (Sell-off) – 5 High-Yield Dividend Safety Stocks

Description: Karen Smith, MD, PhD, MBA, LLM, joins with over 25 years of global pharma and biotech experience, having contributed to more than 20 regulatory approvals Dr Smith's appointment will accelerate Step Pharma's ‘pipeline in a product’ strategy, leveraging her clinical and regulatory expertise to advance dencatistat, afirst-in-class CTPS1 inhibitor across multiple cancer and blood disorder indicationsAppointment follows Step Pharma’s recently announced €38 million Series C financing Saint-Genis-Pouil

Description: Bristol Myers Squibb (BMY) just reported new 52-week Phase 3 trial results for Sotyktu in adults with active psoriatic arthritis. The results show continuous clinical benefit, a steady safety profile, and evidence of joint damage limitation. See our latest analysis for Bristol-Myers Squibb. Bristol-Myers Squibb has been in the spotlight thanks to a steady stream of late-stage trial successes and high-profile partnerships, but the company’s share price reflects ongoing caution, with a 1-year...

Description: DelveInsight's Basal Cell Nevus Syndrome Market Insights report includes a comprehensive understanding of current treatment practices, basal cell nevus syndrome emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into leading markets (the US, EU4, UK, and Japan).

Description: Some of the largest drugmakers in the world are trading at attractive valuations. Are they worth buying?

Description: As earnings season accelerates, pharma heavyweights LLY, MRK, ABBV, BMY and GILD prepare to reveal their Q3 results amid a strong sector start.

Description: Bristol-Myers Squibb (BMY) said Monday that new data from a pivotal phase 3 trial showed that its ps

Description: Halozyme Therapeutics (HALO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Description: Bristol-Myers Squibb's Q3 results hinge on rising demand for new therapies like Opdivo and Camzyos amid legacy-drug declines.

Description: Besides Wall Street's top-and-bottom-line estimates for Bristol Myers (BMY), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2025.

Description: PRINCETON, N.J., October 27, 2025--BMS Presents Two Late-Breaking Presentations Demonstrating Sotyktu (deucravacitinib) Efficacy in Psoriatic Arthritis and Systemic Lupus Erythematosus

Description: Avidity Biosciences (RNA) has agreed to be acquired by Novartis (NVS) for $72 per share in a deal th

Description: Advances made in preclinical pipeline addressing neurodegenerative diseases Evotec receives US$ 25 m payment to support continued progression of joint programs HAMBURG, DE / ACCESS Newswire / October 27, 2025 / Evotec SE (Frankfurt Stock Exchange: ...

Description: PRINCETON, N.J., October 25, 2025--BMS Presents Encouraging Data from Phase 1 Breakfree-1 Study of CD19 NEX-T™ CAR T Cell Therapy in Three Chronic Autoimmune Diseases at ACR.

Description: Bristol Myers edges past Pfizer as the stronger oncology pick, backed by new drug launches, acquisitions and pipeline strength

Description: If you are weighing your next move with Bristol-Myers Squibb, you are definitely not alone. The stock has been on a rollercoaster, and plenty of investors are scratching their heads right now, asking whether the tough run offers a rare opportunity or signals deeper risks. Just in the past week, shares nudged up 1.8%, offering a glimmer of optimism. Yet, zoom out, and the scars of a challenging year are clear, with Bristol-Myers Squibb still down nearly 22% for 2024 and more than 30% over...

Description: We recently published Top 10 Trending Stocks Everyone’s Watching in Q4. Bristol-Myers Squibb Company (NYSE:BMY) is one of the trending stocks everyone’s watching. Morningstar’s Dave Sekera said in a recent program on Schwab Network that BMY is one of the top deep value stocks today. The analyst mentioned the stock’s dividend yield and valuation: “Well, […]

Description: Surging multibillion dollar acquisitions and a pipeline of innovative therapies define the current landscape. A strong focus on oncology theranostics, supported by new regulatory approvals, is rapidly advancing personalized cancer treatment possibilities.Chicago, Oct. 23, 2025 (GLOBE NEWSWIRE) -- The global radiopharmaceuticals market was valued at US$ 6.8 billion in 2024 and is expected to reach US$ 13.4 billion by 2033, growing at a CAGR of 7.8% during the forecast period 2025–2033. The radiop

Description: Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Description: Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Description: Motley Fool analysts Karl Thiel, Rick Munarriz, and Tim Beyers offer up three stocks that face dark clouds they can see through.

Description: Bristol Myers Squibb (BMY) closed at $44.54 in the latest trading session, marking a +2.18% move from the prior day.

Description: These five top dividend stock picks are waiting for growth and income investors to step up to the plate. Plus, they are rated Buy at top firms on Wall Street

Description: Bristol Myers leans on new drugs like Opdivo and Reblozyl to offset pressure from generics as its Growth Portfolio drives stability.

Description: Pfizer's Q3 results are set to reveal mixed trends across non-oncology drugs, with strong Eliquis and Paxlovid sales offset by weakness in Abrysvo and Xeljanz.

Description: They are both yielding above 5%.

Description: The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.

Description: SystImmune Inc. (SystImmune), a clinical-stage biotechnology company, and Bristol Myers Squibb (NYSE: BMY) today announced the oral presentation of the first disclosure of the safety and efficacy data from the global phase I US-Lung-101 study (NCT05983432) of iza-bren (BL-B01D1), a potentially first-in-class EGFR x HER3 bispecific antibody-drug conjugate (ADC), at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany. Iza-bren is jointly developed by SystImmune and Br

Description: LegalMatch Highlight Critical Legal Considerations in Major Business Mergers and Acquisitions RENO, NEVADA / ACCESS Newswire / October 17, 2025 / Following the recent $1.5 billion acquisition of privately held Orbital Therapeutics by Bristol Myers ...

Description: New initiative aims to build capacity in high-prevalence areas to increase screening and prevention of hemoglobinopathies NORTHAMPTON, MA / ACCESS Newswire / October 17, 2025 /PATH has launched a groundbreaking initiative to address the rising burden ...